Pipecuronium (bromide)

C[C@@]1([C@H]2OC(C)=O)[C@](C[C@@H]2N3CC[N+](C)(C)CC3)([H])[C@@](CC[C@]4([H])[C@@]5(C[C@H](N6CC[N+](C)(C)CC6)[C@@H](OC(C)=O)C4)C)([H])[C@]5([H])CC1.[Br-].[Br-]

[1]Tassonyi E, et al. Reversal of Pipecuronium-Induced Moderate Neuromuscular Block with Sugammadex in the Presence of a Sevoflurane Anesthetic: A Randomized Trial. Anesth Analg. 2015 Aug;121 (2) :373-80.|[2]Tassonyi E, et al. Reversal of Deep Pipecuronium-Induced Neuromuscular Block With Moderate Versus Standard Dose of Sugammadex: A Randomized, Double-Blind, Noninferiority Trial. Anesth Analg. 2018 Dec;127 (6) :1344-1350.|[3]Alánt O, et al. First clinical experience with a new neuromuscular blocker pipecurium bromide. Arzneimittelforschung. 1980;30 (2a) :374-9.|[4]Töröcsik A, et al. Characterization of somatodendritic neuronal nicotinic receptors located on the myenteric plexus. Eur J Pharmacol. 1991 Sep 24;202 (3) :297-302.|[5]Kárpáti E, et al. Investigation of neuromuscular blocking agents at Richter Ltd. Acta Pharm Hung. 2002;72 (1) :37-48.